UroGen Pharma Ltd. (NASDAQ:URGN) Receives $43.70 Average Price Target from Analysts

Shares of UroGen Pharma Ltd. (NASDAQ:URGN) have been assigned a consensus rating of “Buy” from the six ratings firms that are covering the company, MarketBeat reports. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $43.70.

Several research firms recently commented on URGN. HC Wainwright reissued a “buy” rating and issued a $60.00 price objective on shares of UroGen Pharma in a research note on Tuesday, October 15th. EF Hutton Acquisition Co. I upgraded shares of UroGen Pharma to a “strong-buy” rating in a research report on Monday, October 14th. D. Boral Capital restated a “buy” rating and set a $25.00 price target on shares of UroGen Pharma in a research report on Thursday, January 23rd. Finally, Oppenheimer reiterated an “outperform” rating and issued a $40.00 price objective on shares of UroGen Pharma in a report on Wednesday, October 16th.

UroGen Pharma Stock Up 2.3 %

URGN stock opened at $10.48 on Friday. UroGen Pharma has a 52 week low of $9.78 and a 52 week high of $20.70. The company has a quick ratio of 8.77, a current ratio of 9.00 and a debt-to-equity ratio of 4.77. The firm has a 50-day simple moving average of $11.20 and a 200-day simple moving average of $12.90. The stock has a market capitalization of $245.76 million, a P/E ratio of -3.33 and a beta of 1.09.

UroGen Pharma (NASDAQ:URGN) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.55) EPS for the quarter, topping the consensus estimate of ($0.84) by $0.29. The firm had revenue of $25.20 million for the quarter, compared to analysts’ expectations of $24.22 million. During the same quarter last year, the firm posted ($0.68) earnings per share. Equities analysts forecast that UroGen Pharma will post -3.1 earnings per share for the current fiscal year.

Hedge Funds Weigh In On UroGen Pharma

A number of institutional investors have recently bought and sold shares of the company. Coastal Bridge Advisors LLC grew its holdings in shares of UroGen Pharma by 4.1% during the 2nd quarter. Coastal Bridge Advisors LLC now owns 38,500 shares of the company’s stock worth $646,000 after purchasing an additional 1,500 shares during the period. China Universal Asset Management Co. Ltd. boosted its stake in UroGen Pharma by 90.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 8,100 shares of the company’s stock worth $103,000 after buying an additional 3,856 shares during the period. BNP Paribas Financial Markets increased its position in shares of UroGen Pharma by 221.8% during the third quarter. BNP Paribas Financial Markets now owns 8,546 shares of the company’s stock valued at $109,000 after acquiring an additional 5,890 shares during the last quarter. Tidal Investments LLC raised its stake in shares of UroGen Pharma by 19.1% in the 3rd quarter. Tidal Investments LLC now owns 37,595 shares of the company’s stock valued at $477,000 after acquiring an additional 6,030 shares during the period. Finally, SG Americas Securities LLC lifted its holdings in shares of UroGen Pharma by 44.1% in the 4th quarter. SG Americas Securities LLC now owns 20,269 shares of the company’s stock worth $216,000 after acquiring an additional 6,207 shares during the last quarter. 91.29% of the stock is owned by hedge funds and other institutional investors.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.